Tech Company Financing Transactions
Cellectar Biosciences Funding Round
Cellectar Biosciences, operating out of Florham Park, scored $140 million in funding from Nantahala Capital Management, Balyasny Asset Management and Janus Henderson Investors.
Transaction Overview
Company Name
Announced On
5/5/2026
Transaction Type
Debt
Amount
$140,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This oversubscribed financing provides important validation of our strategy to pursue accelerated approval in the US and conditional marketing approval in Europe for iopofosine, while supporting our plans to initiate a global confirmatory study in the fourth quarter of 2026.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
100 Campus Dr. 207
Florham Park, NJ 07932
USA
Florham Park, NJ 07932
USA
Phone
Website
Email Address
Overview
Cellectar Biosciences develops targeted cancer therapies using our proprietary PLE platform to precisely treat tumors while minimizing harm to healthy tissue. We focus on improving outcomes for patients with advanced cancers where better options are urgently needed. We envision a future where patients with even the most advanced cancers have access to effective, well-tolerated therapies that improve survival and quality of life.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Douglas Swirsky
Chief Executive Officer
James Caruso
Chief Financial Officer
Chad Kolean
VP - Bus. Development
Jarrod Longcor
Browse more venture capital transactions:
Prev: 5/5/2026: Reduciner venture capital transaction
Next: 5/5/2026: XCaliber Health venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs